banner
 
bar

program

slides
bar
 
 

New Frontiers in the Science and Medicine of Osteoporosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period May 10, 2011 through May 10, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

3.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of osteoporosis.

Release Date:

May 10, 2011

Expiration Date:

May 10, 2013

Intended Audience:

  • Rheumatology specialists
  • Endocrinology specialists
  • Osteoporosis specialists
  • Bone metabolism specialists
  • Biologics-focused clinical pharmacists
  • Internal medicine specialists with osteoporosis clinical focus

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

EisaiSupported by an Independent
Educational Grant from Amgen.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

MONE ZAIDI, MD, PhD, FRCP, Hon MD
(Program Chairperson)
Professor of Medicine and Physiology
Director, The Mount Sinai Bone Program
Mount Sinai School of Medicine
New York, NY

Consultant: GSK, Amgen
Speaker's Bureau: Warner Chilcott, Roche/ Genentech



FELICIA COSMAN, MD
Clinical Director, National Osteoporosis Foundation
Medical Director of the Clinical Research Center
Helen Hayes Hospital
Associate Professor of Clinical Medicine
Columbia University
New York, NY

Consultant: Novartis, AMGEN, Eli Lilly, Merck
Speaker's Bureau: Novartis, AMGEN, Eli Lilly, Merck
Grant/Research Support: Eli Lilly




DAVID W. DEMPSTER, PhD
Professor of Clinical Pathology
Columbia University College of Physicians and Surgeons
Director, Helen Hayes Hospital Regional Bone Center
New York, NY

Consultant: AMGEN, Eli Lilly, Merck
Speaker's Bureau: AMGEN, Eli Lilly
Grant/Research Support: Eli Lilly



ROBERTO PACIFICI, MD
Herndon Professor of Medicine
Director, Division of Endocrinology, Metabolism and Lipids
Emory University School of Medicine
Atlanta, GA

Nothing to disclose


STUART SILVERMAN, MD, FACP, FACR

Clinical Professor of Medicine and Rheumatology
David Geffen School of Medicine
University of California
Los Angeles, CA

Consultant: AMGEN, Eli Lilly, Novartis, Pfizer/Wyeth, Roche
Speaker's Bureau: AMGEN, Eli Lilly, Novartis, Pfizer/Wyeth,
Roche, Warner Chilcott
Grant/Research Support: Eli Lilly, Pfizer/Wyeth, Warner Chilcott

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this CME activity, the participants will be able to:

  • Develop a more rigorous scientific understanding and become more clinically proficient at implementing established, new, and emerging strategies for treating postmenopausal women with osteoporosis who are at high risk for fracture
  • Better understand how to risk stratify postmenopausal women with osteoporosis to determine their risk for future fracture based on such factors as history of previous osteoporotic fracture(s) and other FRAX®-linked features that place them at high risk for fractures
  • Better understand diverse mechanisms of action among osteoporosis treatments, including the basis of action of bisphosphonates and RANKL inhibitors and their effects on osteoclast differentiation, activation, and survival
  • Better understand diverse mechanisms of action among osteoporosis treatments, including the basis of action of bisphosponates and new biologic agents and their effects on osteoclast differentiation, activation, and survival
  • Better understand how to assess treatment failure in post-menopausal women on bisphosphonate-based therapeutic regimens; and, become more clinically proficient at implementing evidence-based strategies with alternative agents in patients who are responding sub-optimally to osteoporosis treatment
  • Become more clinically proficient at evaluating patients whose medication compliance, persistence, and/or regimen adherence are compromised by intolerance and/or adverse side effects to osteoporosis therapy
  • Better understand the clinical results and implications of landmark trials evaluating osteoporosis therapies in patients at high risk for fracture, with a focus on multi-site BMD stabilization/improvement and fracture risk reduction at vertebral, hip and non-vertebral sites over an extended treatment duration
  • Better understand the clinical implications of well-conducted trials evaluating the safety and efficacy of anti-osteoporosis therapies for increasing BMD and reducing fractures at multiple sites in postmenopausal women at high risk for fracture

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Educational Objectives:

Upon completion of this CME activity, the participants will be able to:

  1. Apply evidence-based strategies that may prolong survival in patients with metastatic breast cancer (MBC) who have received multiple, established chemotherapeutic treatment courses (i.e., heavily treated) with documented remissions
  2. Detail the safety, efficacy, and survival prolongation profiles associated with novel treatments being evaluated for MSB, including the role of nontaxane, microtubule dynamics inhibitors
  3. Review the tolerability factors, outcomes, and evidence-based rationale for the use of microtubule inhibitors in heavily pretreated women with metastatic breast cancer who had already received treatment with anthracycline and a taxane for MBC
  4. Discuss rationale, combination therapy, trial design, and outcome metrics focused on progression-free survival and overall survival in heavily treated patients with MBC
  5. Compare the tolerability, safety, and impact on clinical outcomes of late stage agents for MBC, focusing on comparative value of taxanes versus novel agents (microtubule inhibitors) when used as combination therapy with anthracyclines and similar settings
  6. Compare the side effect profiles of anti-tumor agents used for poorly responsive MBC, focusing on such adverse effects as alopecia and peripheral neuropathy
  7. List optimal approaches to sequencing chemotherapeutic agents for MBC—including anthracyclines, taxanes, capecitabine, and novel microtubule-inhibiting agents—to identify a sequencing strategy that achieves the optimal balance of survival benefits and side effect profiles
  8. Discuss which add-on agents in heavily treated patients with MBC are most effective in prolonging survival and maintaining end-of-live, quality-of-life (QoL)
  9. Compare the side effects of agents (taxanes, capecitabine) to hali-chondrin B-based inhibitors of microtubule dynamics, and how the mechanism of action that produce microtubule growth suppression can impact side effect profiles, overcome drug resistance observed with standard agents used for sequenced therapy, and prolong survival in MBC

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

Actonel
Alendronate
Bisphosphonate
BMD
BMI
Bone
Bone Quality
Macro-architecture
Boniva
Calcitonins
Calcium
Cathepsin K
Denosumab


Estrogen
Estrogen-Progestin Combinations
Evista
Fortical
Fosamax
Fractures
FRAX
HORIZON
Ibandronate
Miacalcin
Micro-architecture
National Osteoporosis

Foundation
NOF
osteopenia
Non-Vertebral
Odanacatib
ODN
Osteoblasts
Osteoclast
Osteoporosis
Prolia
Raloxifene
RANK Ligand
RANKL Inhibitor

Denosumab
Reclast® IV
Remodeling
Risedronate
Sclerosteosis
Sclerostin
SOST
Teriparitide
Trabecular number
Vertebral
Vitamin D
WHO Bone Density Criteria
Osteoporotic
Zoledronic Acid